Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period.
Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion.
A biopharmaceutical research team taking notes in front of a laboratory's microscope.
The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential.
Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many.
While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Those who invested in Aurubis (ETR:NDA) five years ago are up 66%
Aurubis AG (ETR:NDA) shareholders might be concerned after seeing the share price drop 14% in the last quarter. On the bright side the returns have been quite good over the last half decade. It has returned a market beating 51% in that time. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Over half a decade, Aurubis managed to grow its earnings per share at 32% a year. The EPS growth is more impressive than the yearly share price gain of 9% over the same period. So it seems the market isn't so enthusiastic about the stock these days. The reasonably low P/E ratio of 8.82 also suggests market apprehension. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Aurubis' TSR for the last 5 years was 66%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. Aurubis provided a TSR of 15% over the last twelve months. But that return falls short of the market. The silver lining is that the gain was actually better than the average annual return of 11% per year over five year. This could indicate that the company is winning over new investors, as it pursues its strategy. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Aurubis has 2 warning signs (and 1 which is concerning) we think you should know about. But note: Aurubis may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
an hour ago
- New York Post
Popular dried fruit pulled from shelves in 19 states
A recall of certain cases of Floria Dried Apricots is underway due to their packaging not disclosing the fruit contains sulfites. Turkana Food Inc. issued a recall for 352 cases of the dried fruit Thursday through an announcement published on the Food and Drug Administration's (FDA) website. Advertisement The dried apricots have 200-gram paper packaging. The move was precipitated by 'routine sampling performed by the New York State Department of Agriculture and Markets' that found the recalled dried apricots 'contained Sulfites that were not listed on the product labelling,' the FDA recall notice said. Companies often use sulfites as a preservative in food and drinks, but some people can have allergic reactions to them. The dried apricots lacking the declaration about sulfites have expiration date of November 2026. Advertisement They also have the lot number '440090478-15-333' and the UPC label '2539560010,' according to the recall notice. Shoppers who bought Floria Dried Apricots with that particular lot number 'should not consume the product,' the recall notice said. Turkana Food Inc. recalled 352 cases of the dried fruit. zigres – Instead, they should return the product to the store where it was purchased for a refund. Advertisement There haven't been any reported illnesses from the undeclared sulfites. According to the FDA, Turkana Food distributed the recalled dried apricots in the following states: Florida Kentucky Virginia New York New Jersey Tennessee Massachusetts Texas Illinois Indiana Michigan Rhode Island Pennsylvania North Carolina Maryland Ohio Alabama Missouri California The company and the FDA are investigating to 'correct the issue with the manufacturer,' according to the FDA notice. Advertisement In the meantime, it has stopped producing and distributing them. The FDA issued the recall in 19 states including New York, New Jersey and Pennsylvania. REUTERS Turkana Food, headquartered in New Jersey, describes itself as a 'family-owned and operated ethnic food distributor.' It serves independent supermarkets, chain stores and institutions, according to its website.
Business Insider
an hour ago
- Business Insider
Why IONQ, RGTI and QBTS are Worth the Risk in Quantum Computing
Quantum computing stocks are high-risk, high-reward plays, where the tech still feels futuristic, but the potential upside could be transformative for your portfolio. While giants like NVIDIA (NVDA) and Alphabet (GOOGL) have stakes in the field, pure-play names like IonQ (IONQ), Rigetti Computing (RGTI), and D-Wave Quantum (QBTS) are gaining serious traction. Confident Investing Starts Here: Each is taking a distinct approach in a sector expected to grow significantly over the next decade. With quantum tech reaching what Nvidia's Jensen Huang recently called an 'inflection point,' these companies are riding a powerful wave of both investor excitement and tangible technological progress. IonQ (NYSE:IONQ) | The Trapped-Ion Powerhouse IonQ is shaping up to be the quarterback of the quantum computing world—everyone's watching, and for good reason. Their trapped-ion technology, which uses charged atoms suspended in electromagnetic fields, produces qubits with exceptional coherence times, translating to more stable and reliable calculations. They've already surpassed 100 qubits, and their systems are available across Amazon (AMZN), Microsoft (MSFT), and Google Cloud, making IonQ a top choice for developers building quantum applications. In Q1, IonQ posted $7.6 million in revenue and forecasted full-year revenue between $75–$95 million, nearly doubling last year's figure, while trimming losses to $0.14 per share from $0.19. The buzz lately? Their aggressive M&A strategy. IonQ recently acquired Lightsynq Technologies to accelerate the development of fault-tolerant quantum systems and invested $1 billion in Oxford Ionics to boost R&D, aiming to scale up to 2 million physical qubits by 2030. They've also forged partnerships with heavyweights such as AstraZeneca and Nvidia in quantum-powered drug discovery and secured a key contract under DARPA's Quantum Benchmarking Initiative. Yes, a $10.4 billion market cap is steep given current revenues, but the long-term thesis hinges on IonQ's strategic partnerships, cloud integration, and early mover advantage potentially paying off for investors willing to ride out the volatility. Is IonQ a Buy, Hold, or Sell? Currently, most analysts are bullish on IONQ stock. The stock features a Strong Buy consensus rating based on four Buy and one Hold ratings assigned in the past three months. No analyst rates the stock a sell. IONQ's average stock price target of $43 implies ~11% upside over the next twelve months, despite shares having already rallied about 400% since this time last year. Rigetti Computing (NASDAQ:RGTI) | The Superconducting Maverick Rigetti's story is a bit more turbulent, but still intriguing. Their superconducting gate-based systems are built for speed, executing operations in just 60–80 nanoseconds, far faster than ion-based platforms. That kind of performance is ideal for time-sensitive workloads, such as financial modeling and AI. As a vertically integrated company, Rigetti controls everything from chip design to cloud access, positioning itself for potential large-scale growth. Their 84-qubit Ankaa-3 system debuted in Q1, and they're targeting enterprise clients, including HSBC and Moody's. However, the financial picture is rough. Q1 revenue dropped 52% to $1.47 million, and the company reported a staggering $200.99 million net loss on just $10.79 million in revenue for 2023, highlighting a steep burn rate. Still, Rigetti isn't standing still. They landed a $35 million deal with Quanta Computer, secured a £3.5 million UK consortium lead focused on quantum error correction, and earned DARPA support—solid wins that keep them relevant. Looking ahead, analysts expect revenue to grow to $23 million in 2026 and $38 million in 2027. It's a high-risk play, but if execution improves, Rigetti could be at the start of a long-term turnaround. Is Rigetti Stock a Good Buy? On Wall Street, Rigetti stock carries a Strong Buy consensus rating based on five unanimous Buy ratings. No analyst rates the stock a hold or a sell. RGTI's average stock price target of $15 implies almost 24% upside potential over the next twelve months. D-Wave Quantum (NYSE:QBTS) | The Tempered All-Star D-Wave Quantum is taking a different path—and making no apologies for it. Their quantum annealing technology, designed for optimization tasks like supply chain logistics and drug discovery, is already producing real-world results. Their Advantage2 system, with over 4,400 qubits, recently completed a magnetic simulation in minutes—something a classical supercomputer would take a million years to solve, according to a Science journal paper. In Q1, revenue hit a record $15 million, a sixfold increase year-over-year, with strong momentum expected to continue. The stock has been on a tear, skyrocketing 1,281% over the past year, far outpacing IonQ's 402% and Rigetti's 840%. Their Leap cloud platform is available in 40+ countries and serves 25 Forbes Global 2000 clients, showcasing real commercial traction for quantum. But with a $5.22 billion market cap and a price-to-sales ratio nearing 200x, the valuation is steep and heavily speculative. The key question is whether D-Wave's annealing approach can hold its edge as gate-based systems advance. It's still early days, and the verdict remains uncertain—but for now, D-Wave is proving that practical quantum solutions might not be as far off as once thought. Is D-Wave a Good Stock to Buy? D-Wave is currently covered by six Wall Street analysts, all of whom hold a bullish outlook. The stock carries a Strong Buy consensus rating with all six analysts assigning a Buy rating over the past three months. However, QBTS's average price target of $13 suggests approximately 18% downside potential over the next twelve months. Why Roll the Dice? Quantum computing stocks are far from safe bets—they come with deep losses, sky-high valuations, and intense competition from tech giants like Google and IBM. Still, IonQ's enterprise-ready systems, Rigetti's speed-focused tech, and D-Wave's real-world traction make them standout players in a field with extensive long-term commercialization capacity. While the future of their revenues and profitability remains uncertain, all three deserve a spot on investor watchlists.
